Iterum Therapeutics plc has announced a significant agreement through its subsidiary, Iterum Therapeutics US Limited, with EVERSANA Life Science Services, LLC for the commercialization of ORLYNVAHTM in the United States. Under this agreement, Eversana will provide a comprehensive range of services, including sales, marketing, logistics, and regulatory support, among others, to facilitate the US launch and distribution of the product. This partnership is set to last until five years post-commercial launch, with provisions for termination under specific conditions. Iterum will retain responsibility for legal, regulatory, and manufacturing aspects while Eversana will be the exclusive provider of the agreed-upon services, ensuring compliance with applicable laws.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.